NCT06697886

A Study of the Efficacy and Safety of Antiwei Granules in the Treatment of Common Cold

To Evaluate the Efficacy and Safety of Antiwei Granules in the Treatment of Common Cold (Wind-cold Syndrome) in a Multicenter, Randomized, Double-blind, Placebo-controlled Phase Ⅲ Clinical Trial

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 480 (estimated)
• Sponsor: Tasly Pharmaceutical Group Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

To further evaluate the efficacy and safety of Antiwei granule in the treatment of common cold (wind-cold syndrome)

Conditions

• Common Cold

Interventions

Type	Name	Description
DRUG	Antiwei Granules	During the 3-day treatment period, participants will receive 9 sacks of Antiwei granules. Oral administration, 1 sack (6g) per time, 3 times daily.
DRUG	Antiwei Granules Placebo	During the 3-day treatment period, participants will receive 9 sacks of Antiwei granules. Oral administration, 1 sack (6g) per time, 3 times daily.

Timeline

• Start date: 2023-11-16
• Primary completion: 2025-06-25
• Completion: 2025-07-01
• First posted: 2024-11-20
• Last updated: 2024-11-20

Locations

24 sites across 1 country: China